The QualityStocks Daily Monday, January 10th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(BBLG) $5.3900 +57.14%

Schaeffer's(ZNGA) $8.4400 +40.67%

MarketBeat(APR) $37.4800 +26.11%

The QualityStocks Daily Stock List

Bone Biologics (BBLG)

QualityStocks reported earlier on Bone Biologics (BBLG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bone Biologics Corp. (NASDAQ: BBLG) is a medical device firm that is centered on bone regeneration in spinal fusion, through the use of recombinant human proteins.

The firm has its headquarters in Burlington, Massachusetts and was incorporated in 2004 by Benjamin Wu, Chia Soo and Eric Kang Ting. It serves consumers in the United States.

The company’s aim is to improve clinical outcomes and decrease total healthcare costs linked to spinal fusion. It is party to a license agreement with UCLA Technology Development Group, which entails the development and commercialization of its NELL-1 product that has been developed for spinal-fusion applications.

The enterprise’s pipeline comprises of its combination product known as NELL-1/DBX, which is an osteo-stimulative recombinant protein which offers target control over bone regeneration without causing inflammation or leading to poor bone formation. This osteopromotive growth factor has shown that it can effectively increase the quality and quantity of bone across large and small animal models. It is also developing a device indicated for spinal fusion procedures in patients with degenerative disc disease at a single level from L4-21, known as the NELL-1/DBX Fusion Device. The enterprise’s platform technology has applications in delivering better outcomes in the specialties of sports, interventional radiology, neurosurgery, plastic reconstruction, general orthopedic, orthopedic and spinal medicine.

With the osteoporosis drugs market set to grow exponentially during this decade, the firm is well positioned to grow significantly as it addresses unmet patient needs by offering technologies that improve bone repair and regeneration in areas where present options offer sub-optimal outcomes.

Bone Biologics (BBLG), closed Monday's trading session at $5.39, up 57.1429%, on 66,930,259 volume with 310,910 trades. The average volume for the last 3 months is 67.074M and the stock's 52-week low/high is $3.23/$7.1219.

International Battery Metals Ltd. (RHHNF)

QualityStocks, Wealth Insider Alert and TradersPro reported earlier on International Battery Metals Ltd. (RHHNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets, International Battery Metals Ltd. is an advanced disruptive technology enterprise. The Company’s emphasis is on lithium brine extraction. It is in the process of creating and applying intellectual property (IP) related to lithium extraction from brines. The Company previously went by the name Rheingold Exploration Corp. It changed its name to International Battery Metals Ltd. in August of 2017. Established in 2010, International Battery Metals is based in Vancouver, British Columbia.

Lithium extraction from brine is the next disruptive technology. Third generation patent pending technology allows lithium extraction from South American salars and drill holes associated with the oil and gas industry globally. International Battery Metals’ competitive advantage is that it produces high quality battery grade lithium for lithium-ion batteries.

Extraction specifically targets lithium chloride; other salts stay in the brine. Moreover, there is a small environmental footprint: no salt piles, waste, water ponds or rock piles. It is efficient simple processing, a low carbon footprint, and allows for very low fresh water usage.

International Battery Metals has a technical team with wide-ranging proven experience in lithium extraction projects. The Company is targeting low-cost production of battery grade lithium and has innovative mobile extraction units for efficient timely deployment. Its focus is to bring on resources quickly with high recovery rates.

International Battery Metals Ltd. (RHHNF), closed Monday's trading session at $3.11, up 30.6723%, on 387,352 volume with 635 trades. The average volume for the last 3 months is 387,352 and the stock's 52-week low/high is $0.2599/$3.57.

Adamis Pharmaceuticals (ADMP)

MarketBeat, StockMarketWatch, MarketClub Analysis, AllPennyStocks, BUYINS.NET, QualityStocks, TraderPower, The Street, Barchart, Investors Insights, Microcap MarketPlace, Money Morning, StreetInsider, The Campaign for a Sound Dollar, Schaeffer's,, Wall Street Resources, Triple Crown Stocks, Daily Trade Alert, Dynamic Wealth Report, FeedBlitz, Investing Futures, Investors Alley, TradersPro, SmallCapVoice, The Online Investor, Microcap Money, StocksEarning, Wealth Insider Alert, SeriousTraders and Trades Of The Day reported earlier on Adamis Pharmaceuticals (ADMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (FRA: CY3B) is a specialty biopharmaceutical firm which is engaged in the development, commercialization and distribution of pharmaceutical products in the therapeutic areas of respiratory, allergy, infectious, immunology and oncology diseases.

Adamis Pharmaceuticals Corp. serves consumers in the United States and is based in San Diego, California. The firm was established in June 2006 and has a licensed vaccine technology known as somatic transgene immunization technology.

Adamis Pharmaceuticals Corporation’s product portfolio includes the epinephrine injection pre-filled syringe, which is used in the emergency treatment of acute allergic reactions, include anaphylaxis. The firm also provides dry powder products made up of naloxone injection product candidates indicated for the treatment of an opioid overdose, APC-6000; APC-8000 also known as Tadafil which is indicated for the treatment of erectile dysfunction; APC-1000 or beclomethasone, a metered dose inhaler product indicated for asthma and APC-4000 or fluticasone, indicated for the treatment of asthma. Additionally, the firm offers women’s and men’s health products, topical compounds for pain, urological preparations, injectables, hospital outsourcing product, hormone replacement therapies, corticosteroids and some animal veterinary pharmaceutical products.

Adamis Pharmaceuticals Corporation recently publicized its submission of a new investigational drug to the FDA developed as a coronavirus treatment. The drug; Tempol, has shown both potent antioxidant, anticoagulant and anti-inflammatory activity, which shows that the drug could play a crucial role in not only treating the coronavirus but also preventing hospitalization. With new variants of the virus coming up, new therapies will be needed. Tempol may help fill this role, especially if the new vaccines aren’t effective in protecting against these new mutations.

Adamis Pharmaceuticals (ADMP), closed Monday's trading session at $0.73, up 26.9565%, on 38,371,991 volume with 44,650 trades. The average volume for the last 3 months is 38.352M and the stock's 52-week low/high is $0.551/$2.34.

MGT Capital Investments, Inc. (MGTI)

QualityStocks, MarketBeat, MarketClub Analysis, StocksEarning, Promotion Stock Secrets, TopPennyStockMovers, PoliticsAndMyPortfolio, Wall Street Mover and StreetInsider reported earlier on MGT Capital Investments, Inc. (MGTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MGT Capital Investments, Inc. is a Bitcoin miner with operations at hosted facilities in the States of Colorado and Ohio. In addition, it has started construction of an owned facility in Georgia. The Company is pursuing an expansion model to secure low cost power and grow its crypto assets. MGT Capital Investments has its head office in Durham, North Carolina.

Unlike traditional currencies, Bitcoin operates on the basis of a “public ledger system”. For Bitcoin transactions to be confirmed, avoiding the same Bitcoin being spent twice, Bitcoin miners are needed. Bitcoin mining plays an intricate part in the Bitcoin Blockchain ecosystem. Without Bitcoin miners, the ability to keep the public ledger system correct would be impossible.

MGT Capital Investments first started mining Bitcoin in September of 2016, in Washington State. In 2017, MGT opened an additional mining facility in Northern Sweden, which it has since wound down. At the end of Q3 2018, in response to the underperformance of MGT’s Swedish facilities, management shifted its main operations to North America. The transition was made to materially decrease the Company’s costs while establishing the conditions for stable, long-term growth.

Previously, MGT determined to consolidate its activities going forward in Company-owned and managed facilities in LaFayette, Georgia. Located adjacent to a utility substation, the several acre property has access to greater than 20 megawatts (MW) of low-cost power. MGT also ordered transformers with a total load capacity of 12.5 MW to accommodate the initial phase of the project. MGT has started the construction and physical site development.

As of January 31, 2020, the Company was operating 1,500 new generation Bitcoin miners collectively rated at approximately 80 Ph/s at its facility in LaFayette, Georgia. All miners were purchased from Bitmain and possess enough computational power to mine 38 Bitcoin per month at the current Difficulty Rate.* The total electrical load at this production level is estimated at slightly under 4.0 MW.

MGT’s miners are housed in five modified shipping containers, including two manufactured by Bit5ive LLC of Miami. As an early investor and design consultant, the Company receives a modest royalty participation in all sales of Pod5ive containers. To date, we have been very satisfied with the ease of deployment and operating effectiveness of these units.

Phase I of the LaFayette site is structurally complete and awaiting final grading and landscaping. The entire facility, including the land, five 2500 KVA 3-phase transformers, the mining containers and the miners, are owned by MGT. As we are presently using only one-third of the available electrical load, the Company is exploring ways to grow its current operations. Also of note, MGT has successfully terminated all third-party hosting agreement and has sold all but approximately 1,000 of its S9 Antminers.

MGT Capital Investments, Inc. (MGTI), closed Monday's trading session at $0.019, up 25.6614%, on 19,025,322 volume with 460 trades. The average volume for the last 3 months is 19.025M and the stock's 52-week low/high is $0.0135/$0.298.

Smart Share Global (EM)

Vantage Wire, The Street, Streetwise Reports, StreetInsider, Street Insider, Schaeffer's, MarketBeat, InvestorGuide, BUYINS.NET, AlphaPennyStock and AllPennyStocks reported earlier on Smart Share Global (EM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Smart Share Global Ltd (NASDAQ: EM) is a consumer tech firm that is engaged in the provision of mobile device charging services.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 2017. The firm is also known as Energy Monster. It serves consumers in China.

The company’s mission is to energize everyday life while maintaining its position as the biggest provider of mobile device charging services in China, with the #1 market share.

The enterprise offers mobile device charging services via offline and online networks. It provides services through its power banks placed in POIs (points of interest) which are operated by its locations partners, including transportation hubs, hotels, shopping centers, restaurants, entertainment venues and public spaces. Consumers can begin to use its products by finding its cabinet locations via various mini programs or by finding its cabinets at a point of interest. These mini programs show consumers a map view with the enterprise’s cabinet locations. The enterprise also sells and rents power banks. As of September 2021, the enterprise had 5.8 million power banks in 820,000 points of interests, across over 1,700 county-level districts and counties in China.

The company is focused on launching new network partner campaigns, which will bring in additional revenue as well as investors into the company while extending their consumer reach. This is in addition to focusing on optimizing its internal operational and management structures, optimizing incentive fee structures for its location partners and accelerating key account coverage.

Smart Share Global (EM), closed Monday's trading session at $1.68, off by 4.5455%, on 154,788 volume with 856 trades. The average volume for the last 3 months is 154,794 and the stock's 52-week low/high is $1.20/$10.00.

PARTS iD Inc. (ID)

MarketBeat, MarketClub Analysis, InvestorPlace, Investor Ideas and FeedTheBull reported earlier on PARTS iD Inc. (ID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PARTS iD Inc. (NYSE American: ID) is a digital commerce firm that is focused on the sale of automotive parts and accessories.

The firm has its headquarters in Cranbury, New Jersey and was incorporated in 2008. It operates as part of the automotive parts, accessories and tire stores industry. The firm has two companies in its corporate family and serves consumers around the globe.

The company is technology-driven and focused on creating unique user experiences and custom infrastructure within niche markets. Its vision is to create a one-stop digital commerce destination for the automotive accessories and parts market that offers consumers direct access to the parts and accessories they require.

The enterprise’s data catalog has been designed to tie every vehicle with parts that fit their specific YMM (Year-Make-Model), which include their engine size, variations of sub-model, drivetrain type and transmission type. The catalog also recommends other products, including tools needed to install the purchased accessories and parts. The enterprise provides automobile accessories, tires and wheels, lighting and repair parts, performance parts, and parts and accessories for RVs/campers, powersports, motorcycles, semi-trucks, outdoor sports, boats, camping gear and tools. It sells branded and private label products via different platforms, including,,,,, and

The firm recently launched its EV specialty shop on its retail site. This milestone will help the firm penetrate the growing electric vehicle market, which will extend its consumer reach and bring in more revenues as well as investors into the firm. This will be good for the firm’s growth.

PARTS iD Inc. (ID), closed Monday's trading session at $2.08, off by 2.8037%, on 54,101 volume with 295 trades. The average volume for the last 3 months is 54,101 and the stock's 52-week low/high is $1.91/$9.50.

Oncternal Therapeutics (ONCT)

MarketClub Analysis, StockMarketWatch, MarketBeat, StreetInsider and BUYINS.NET reported earlier on Oncternal Therapeutics (ONCT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oncternal Therapeutics Inc. (NASDAQ: ONCT) (FRA: GTU2) is a clinical-stage biopharmaceutical firm that is focused on developing oncology therapies for cancer patients with critically unmet medical needs.

The firm has its headquarters in San Diego, California and was incorporated in 1997 by James B. Breitmeyer and David F. Hale. The firm serves consumers in the United States.

The company is party to a research collaboration with Celularity Inc., which entails the evaluation of placental derived-cellular therapies targeting ROR1. It is also party to license agreements with the University of Tennessee Research Foundation, Selexis S.A., Shanghai Pharmaceutical Inc., Georgetown University, and the Regents of the University of California.

The enterprise’s product pipeline is made up of an investigational small molecule dubbed TK216, which inhibits the E26 Transformation Specific family of oncoproteins; and an investigational monoclonal antibody known as zilovertamab (ZILO-301), which is in a phase I/II clinical trial testing its effectiveness in treating patients with B-cell lymphoid malignancies like chronic lymphocytic leukemia and mantle cell lymphoma, when used in combination with ibrutinib. In addition to this, the enterprise develops a CAR-T cell therapy that has been designed to target ROR1 (receptor-tyrosine kinase-like Orphan Receptor 1). The therapy is in preclinical development as a treatment for solid tumors and hematologic cancers.

The company recently revealed that after a successful meeting with the U.S. FDA for its zilovertamab formulation, they would carry on with a phase 3 trial. This brings the promising formulation one step closer to commercialization, which would not only benefit patients with aggressive lymphomas like mantle cell lymphoma but also bring in more investors into the company, which would in turn, boost its growth.

Oncternal Therapeutics (ONCT), closed Monday's trading session at $2.14, up 0.469484%, on 480,654 volume with 2,869 trades. The average volume for the last 3 months is 480,654 and the stock's 52-week low/high is $2.02/$10.56.

Lixte Biotechnology (LIXT)

QualityStocks, TopPennyStockMovers, Wall Street Mover, Real Pennies,, PoliticsAndMyPortfolio, MarketClub Analysis and INO Market Report reported earlier on Lixte Biotechnology (LIXT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) (FRA: 864) is a drug discovery firm that utilizes biomarker technology to identify enzyme targets associated with severe common ailments and design new compounds to attack these targets.

The firm has its headquarters in East Setauket, New York and was incorporated in 2005, on August 5th by Robert B. Royds and John S. Kovach. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company is party to a collaboration agreement with Oncode Institute, the Netherlands Cancer Institute, and the Spanish Sarcoma Group. It is also party to a clinical trial research agreement with the Research Institute Hospital Inc. and the Moffitt Cancer Center.

The enterprise mainly focuses on protein phosphatases inhibitors which can be used solely or in combination with immune checkpoint blockers, x-ray and/or cytotoxic agents. Its products portfolio is comprised of 2 major categories of compounds that are in different stages of clinical and pre-clinical development. The enterprise develops 2 series of pharmacologically active drugs, which include the LB-200 series for the treatment of cancer, neurodegenerative ailments and chronic hereditary illnesses like Gaucher’s disease; and the LB-100 series, which is made up of new structures that may be useful in the treatment of cancers, as well as metabolic and vascular illnesses.

The company recently announced its latest results from its LB-100 preclinical study which show that the compound grew responsiveness of diverse cancers to immunotherapy. As most patients with cancer don’t respond to immunotherapy, this advancement is a breakthrough in the development of a more effective cancer treatment, which will benefit patients with cancer while boosting the company’s growth.

Lixte Biotechnology (LIXT), closed Monday's trading session at $2.5, up 16.8224%, on 2,663,596 volume with 8,591 trades. The average volume for the last 3 months is 2.668M and the stock's 52-week low/high is $1.1076/$7.19.

Aveo Pharmaceuticals (AVEO)

Schaeffer's, MarketBeat, The Street, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Investors Alley, StreetInsider, Hit and Run Candle Sticks, Promotion Stock Secrets, Zacks, PennyStockScholar, BestOtc,, PoliticsAndMyPortfolio, InvestorPlace, CRWEWallStreet, CRWEFinance, OTCtipReporter, WealthMakers, Wealth Daily, TraderPower, Street Insider, Dynamic Wealth Report, Wall Street Mover, Investopedia, INO Market Report, Wall Street Resources, Greenbackers, PennyToBuck, Eagle Financial Publications, Trading Markets, DrStockPick, Day Trade Alert, CRWEPicks, Wealth Insider Alert, FeedBlitz, PennyOmega, SmallCap Network, Stock Rocket Report, Rick Saddler, Quant Ratings Team, StockHotTips, TradingMarkets, Top Stock Picks, Jason Bond, Pennybuster, Penny Stock Rumble, TopStockAnalysts, Options Elite, TradersPro, Stock Beast and StockOodles reported earlier on Aveo Pharmaceuticals (AVEO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aveo Pharmaceuticals Inc. (NASDAQ: AVEO) (FRA: VPA1) is a biopharmaceutical firm that is engaged in the development and commercialization of medications for patients with cancer.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2001, on October 19th by Kenneth E. Weg, Lynda Chin and Ronald A. DePinho. Prior to its name change in March 2005, the firm was known as Gen Path Pharmaceuticals Inc. The firm serves consumers around the globe.

The company is party to collaboration agreements with Bristol Myers Squibb, AstraZeneca PLC, Kyowa Kirin Co. Ltd, Biogen Idec International GmbH, St. Vincent’s Hospital Sydney Ltd, Biodesix Inc., Novartis International Pharmaceutical Ltd, EUSA Pharma Ltd, and CANbridge Life Sciences Ltd.

The enterprise’s product portfolio comprises of a potent humanized IgG1 monoclonal antibody dubbed Ficlatumuzab, which has been designed to target hepatocyte growth factor and is currently in phase 2 clinical trials evaluating its effectiveness in treating acute myeloid leukemia, pancreatic cancer, and squamous cell carcinoma of the head and neck. It also develops an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor dubbed Fotivda for the treatment of renal cell carcinoma; a potent antibody known as AV-203 for the treatment of human ErbB3; and a formulation dubbed Tivozanib for the treatment of renal cell carcinoma. The enterprise also develops a potent antibody dubbed AV-380 for the prevention and treatment of cachexia.

The firm recently entered into a clinical trial collaboration and supply agreement with NiKang Therapeutics Inc. This collaboration will not only bring in more investors into both firms but also facilitate the advancement of Aveo’stivozanib formulation and NiKang’s NKT2152 program, as part of its combination strategy, bringing them one step closer to helping patients with clear cell renal cell carcinoma.

Aveo Pharmaceuticals (AVEO), closed Monday's trading session at $4.08, off by 2.3923%, on 711,831 volume with 5,326 trades. The average volume for the last 3 months is 724,120 and the stock's 52-week low/high is $3.95/$18.24.

NIO Inc. (NIO)

InvestorPlace, Green Car Stocks, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Daily Trade Alert, Trades Of The Day, The Online Investor, Kiplinger Today, StreetInsider, Zacks, StocksEarning, StockMarketWatch, BUYINS.NET, Cabot Wealth, QualityStocks, INO Market Report, Wealth Insider Alert, CNBC Breaking News, InvestorsUnderground, The Wealth Report, TradersPro, Investopedia, Early Bird, Daily Wealth, wyatt research newsletter, Energy and Capital, InvestorsObserver Team, CRWEWallStreet, InvestorIntel, MarketClub, Investors Alley, Jim Cramer, AllPennyStocks, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and Wealth Daily reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicles (“EVs”) are poised to play a significant role in transportation as numerous countries around the world strive to cut down their greenhouse gas emissions. Unlike conventional diesel-powered vehicles, electric cars rely on a rechargeable lithium-ion battery and an electric motor rather than an internal combustion engine. By eliminating fossil fuels, electric vehicles produce minimal emissions at the tailpipe, making them the perfect vehicle for a green economy. According to a new study, however, electric vehicles aren’t as carbon free as many people may think.

The analysis found that compared to diesel- and petrol-powered cars, producing electric vehicles is more carbon intensive. This is primarily because of the electric vehicles’ batteries, which require several rare minerals to produce. However, drivers in the United Kingdom can make up for that extra carbon after only 7,000 miles of driving. Analysis by the International Council on Clean Transportation (“ICCT”) found that manufacturing an average medium-sized fossil fuel car such as the VW Golf results in around 7.2 tons of carbon emissions. On the other hand, producing an electric vehicle of a similar size produces nearly 9.2 tons of carbon emissions, around 2 tons more than what it takes to produce a similarly sized petrol or diesel car.

But after driving for an estimated 7,061 miles, EV owners in the UK can make up for the “carbon debt.” According to ICCT calculations, an electric car in the UK would produce an average of 35 g of Co2 per km while an average fossil fuel car will produce around 211 g of CO2 per km. Since the average new car in the UK is driven for nearly 10,400 miles a year for the first three years of its life, UK drivers can reach the break-even point after less than a year of driving. ICCT researcher Dr. George Biecker says EV drivers in the UK would reach this point after only a few months as the UK’s electricity grid is heavily reliant on renewable energy.

This means that when UK drivers recharge their cars, they are filling up the vehicles with clean, renewable energy. In the United States, electricity providers are heavily reliant on coal for power production, and this extends the break-even point for American EV drivers. While EV owners in the UK will reach this point after only 7,000 miles of driving, their American counterparts will have to drive for 14,167 miles for their cars to make up their carbon debt.

It is now up to electric vehicle makers such as NIO Inc. (NYSE: NIO) to leverage such research findings as they make a strong case for switching to EVs on environmental sustainability grounds as they reach out to customers.

NIO Inc. (NIO), closed Monday's trading session at $28.91, off by 1.3311%, on 44,833,597 volume with 274,030 trades. The average volume for the last 3 months is 44.024M and the stock's 52-week low/high is $27.52/$66.99.

Gratomic Inc. (CBULF)

equities Canada reported earlier on Gratomic Inc. (CBULF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gratomic (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82) has begun the manufacture of Air Classification units for its Aukam Graphite Project processing plant. According to the announcement, Air Classification is a unique feature of the Namibia-based processing plant, which allows Gratomic to take advantage of the singular properties of vein graphite in an effective and ecologically friendly manner, resulting in the upgrade of carbon content at both the feed-end of the plant and at the final upgrading circuit post processing. The patent-pending technology was developed by Robert Rice, a metallurgical engineer with some five decades of experience in mining and milling engineering projects, including numerous equipment design and applications. He devised the air classification system to eliminate the screening process, which separates ore by size, weight and shape allowing for the fully disseminate minerals to be released and separated from waste material. Gratomic’s use use of the Air Classification systems at its Aukim plant is a first for the mining industry. “Technological advances in mineral processing continuously shape the way in which graphite is economically upgraded into commercial specifications,” said Gratomic CEO and president Arno Brand in the press release. “We consider that this Air Classification technology will revolutionize Gratomic's approach in further industrializing assets around the world in an environmentally friendly manner.”

To view the full press release, visit

About Gratomic Inc.

Gratomic is focused on introducing an exceptional anode material to the global electric vehicle and energy storage supply chains. True to its roots as an exploration and mining company, Gratomic aims to achieve full operational capabilities in 2022 on its Aukam Graphite Project and continues to diversify its assets into a multinational company with various projects globally. Large quantities of its naturally high-quality vein graphite have been shipped for testing to confirm its viability as an anode material. Gratomic is confident that the results will provide a unique competitive advantage in its desired target markets. The company's recent collaboration agreement with Forge Nano has advanced the developments on its graphite finalization phase for the micronization and spheronization, as well as the patented Atomic Layer Deposition (“ALD”) coating of its Aukam vein graphite for use in lithium-ion batteries. Forge Nano is a global leader in surface engineering and precision nanocoating technology, using ALD. GRAT has two outstanding off-take purchase agreements with TODAQ and Phu Sumika with contract fulfillment slated to begin in 2021. Gratomic plans to deliver mine-to-market traceability through its partnership with deep-tech company TODAQ by providing documented tracking on all graphite generated at its flagship Aukam Graphite Project. For more information about the company, visit

Gratomic Inc. (CBULF), closed Monday's trading session at $1.05, off by 3.6697%, on 22,665 volume with 43 trades. The average volume for the last 3 months is 22,665 and the stock's 52-week low/high is $0.27369/$1.505.

Comerica Incorporated (CMA)

StockMarketWatch, MarketBeat, The Street, MarketClub Analysis, Daily Trade Alert, Louis Navellier,, Barchart, Zacks, StreetInsider, Kiplinger Today, Trades Of The Day, StreetAlerts, StocksEarning, Schaeffer's, Market Intelligence Center Alert, SmarTrend Newsletters, InvestorPlace, Top Pros' Top Picks, The Online Investor, Daily Markets, Street Insider, Trading Concepts, Greenbackers, Stockhouse, StreetAuthority Daily, CNBC Breaking News, Wealth Insider Alert, Vantage Wire, Daily Wealth, Coattail Investor, GorillaTrades, Average Joe Options, ChartAdvisor, FreeRealTime, Darwin Investing Network, Navellier Growth, Forbes, Insider Wealth Alert, InvestorsObserver Team, MarketWatch, AllPennyStocks, Money Morning, One Hot Stock, Streetwise Reports, The Wealth Report, Trading For Keeps, Trading Markets, TradingMarkets, Wall Street Beauties, WStreet Market Commentary and Money and Markets reported earlier on Comerica Incorporated (CMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shares of Comerica Incorporated (NYSE:CMA) traded at a new 52-week high today of $98.53. This new high was reached on below average trading volume as 232,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares.

Comerica is a financial services company headquartered in Dallas. It is primarily focused on relationship-based commercial banking. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada.

Comerica Incorporated (NYSE:CMA) is currently priced 59.1% above its average consensus analyst price target of $39.57.

In the past 52 weeks, shares of Comerica Incorporated have traded between a low of $55.87 and a high of $98.53 and is now at $96.70, which is 73% above that low price.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

Comerica Incorporated (CMA), closed Monday's trading session at $97.12, up 0.051509%, on 1,342,064 volume with 23,550 trades. The average volume for the last 3 months is 1.321M and the stock's 52-week low/high is $55.87/$98.53.

The QualityStocks Company Corner

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) recently announced that its wholly owned subsidiary, Sapientia Technologies LLC., had launched its better-for-you plant-based twists to 350 Federated Co-operatives Limited Stores – under the COOP Pure Brand. The launch provides Eat Well Group with an additional revenue channel for 2022, as the company plans to scale other product offerings. It also comes only six months after Eat Well Group’s acquisition of Sapientia. “Sapientia created these plant-based twists for consumers who want healthier snack foods offering high proteins and other nutritional values. These snacks are baked, not fried – offering approximately 30% fewer calories and higher nutritional values than their corn-based competitors,” reads a recent article. “Our investment in Sapientia is disrupting the multibillion-dollar snack food market by providing taste and nutrition without compromise,” said Eat Well Group President Marc Aneed. “These plant-based twisted curls deliver the same delicious flavor, crunch and texture as leading snack food brands while providing 3-4 times more protein, 4-5 times more fiber with less fat and calories.” To view the full article, visit

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Monday's trading session at $0.4992, up 5.8188%, on 303,570 volume with 27 trades. The average volume for the last 3 months is 258,070 and the stock's 52-week low/high is $0.135/$1.00.

Recent News

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF)

The QualityStocks Daily Newsletter would like to spotlight Mydecine Innovations Group Inc. (MYCOF).

  • The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding
  • The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs 
  • The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules 
  • Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology
  • Mydecine’s primary focus is the compound psilocybin, which interacts with serotonin receptors in the human body, creating a psychedelic effect
  • The company is currently working on four lead candidates which may be useful in the treatment of PTSD, smoking cessation, and substance abuse

A biotech and digital technology company aiming to transform the treatment of mental health and addiction disorders, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) announced that it has completed a target-based model of the classic psychedelic serotonin receptor 5-HT2A for use in its artificial intelligence (“AI”)-driven drug discovery program. Through this new model, the company will be able to expedite the screening of billions of structures to determine which of the novel compounds will increase binding affinity and enable the continued creation of improved second and third-generation psychedelic molecules for medicinal use. Also today, the company announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the investment community, the financial media and the general public. The services agreement with JBN has a term of six months with a total payment value of $150,000. To view the full press releases, visit and Additionally, it was reported that the University of Texas at Austin recently established a Center for Psychedelic Research and Therapy. This comes months after the state’s governor signed a proposal that instructs the state to conduct research on the benefits and risks of ketamine, MDMA and psilocybin for veterans. Prof. Charles B. Nemeroff, the center’s co-lead, stated that the center would bring more scientific expertise and rigor to study psychedelic therapy. Nemeroff is also the chair of the Department of Behavioral Sciences and Psychiatry at the Dell Medical School. Studies on psychedelics in Western medicine began in the 1950s, receiving mainstream attention. However, after the Controlled Substances Act came into effect in 1971, research on the substances was prohibited until now. And as research into these substances recommences, we are seeing many companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) working to bring to market therapeutic products from various psychedelic compounds.

Mydecine Innovations Group Inc. (NEO: MYCO) (NASDAQ: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction. Founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovations in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other mental health disorders.

Mydecine’s business model combines clinical trials and data outcome, technology and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, ultimately changing the way we treat mental health disorders. The company seeks to bridge the gap between the needs of patients and what the mental health care system currently provides.

Mydecine Innovations Group is headquartered in Denver with international offices in Canada and Europe.

Research and Technology

The invention and development of novel psychedelic and non-psychedelic molecules for medical use is an important part of Mydecine’s research strategy. The company uses molecules found in nature as building blocks to create improved second-generation drugs. This portfolio of new drugs represents major improvements to existing natural products and synthetics, including enhanced safety, efficacy, stability and dosing, as well as reduced side effects.

The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients, along with improved management of dosage and drug behavior for clinicians. Mydecine believes the multibillion-dollar market for mental health and addiction disorder medicines will soon be disrupted amid a resurgence of the study into psychedelics and data showing the immense benefits of these forms of medicine.

The company currently has four lead drug candidates which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation.

Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the conscious and responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.

Market Outlook

The global smoking cessation market is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9 percent from 2018 to 2026. The market for psychedelic therapeutics is in its very early stages. Estimates of current market value and forecasts of expected value in future years are all over the map. Market forecasts range from $6.5 billion by 2030 with a CAGR of 15 percent, to more than $69 billion as soon as 2025, at a CAGR of 8.2 percent. What is clear is that interest in psychedelic therapeutic drugs is expanding rapidly.

Management Team

Joshua Bartch is Chief Executive Officer and Chairman of Mydecine Innovations Group. He is an experienced entrepreneur who co-founded and founded Denver-based dispensary Doctors Orders in 2009. He also founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded, the USA’s most significant and sophisticated legal cannabis wholesale platform.

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, is the Chief Medical Officer of Mydecine. He was formerly Chief of Psychiatry for the Canadian Armed Forces, retiring in 2021 with the rank of colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon and spent his final 20 years of service as a psychiatrist. He maintains academic appointments at Dalhousie University and The University of Ottawa. He is the inaugural CF Brigadier Jonathan C. Meakins CBE, RCMAC, Chair in Military Mental Health at the Royal Ottawa Hospital.

Robert Roscow is Chief Scientific Officer of Mydecine. As a geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. His innovations were applied at Canopy Growth and ebbu, where he ran those companies’ genetics divisions. He has leveraged his expertise to maximize industrial production of cannabinoids in a pharmacological context, resulting in multiple patent filings.

Damon Michaels is Chief Operating Officer of Mydecine. He previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for ebbu, the leading multi-platform cannabinoid research and technology firm based in Colorado. He has held leading roles with multiple large brands throughout the cannabis vertical. He also developed a national snowboard brand.

Mydecine Innovations Group Inc. (MYCOF), closed Monday's trading session at $0.1325, up 18.3036%, on 1,421,481 volume with 344 trades. The average volume for the last 3 months is 1.421M and the stock's 52-week low/high is $0.01/$2.20.

Recent News

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF)

The QualityStocks Daily Newsletter would like to spotlight StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF).

  • StraightUp has hired experienced commodities entrepreneur and economic geologist Rod Husband as its new CEO as it enters 2022 in an expansionist phase
  • Mineral property exploration company StraightUp Resources is building excitement for several properties it has optioned in the gold-producing region of Ontario’s famed Red Lake Mining District
  • StraightUp also acquired a mine in the historic Bullfrog Boom area surrounding Beatty, Nevada during recent months
  • The company recently added a listing on the OTCQB Venture Market and eligibility for electronic clearing and settlement of its transactions through the Depository Trust Company
  • The company has completed heliborne investigations at three of its five Ontario sites, and has confirmed multiple areas of high merit and potential mineralization on one that has previously been unexplored

Going into 2022, precious metals explorer StraightUp Resources (CSE: ST) (OTCQB: STUPF) is welcoming the leadership of new CEO Rod Husband, an accomplished entrepreneur and economic geologist with over 30 years of experience in the international commodity and finance sectors. StraightUp executive Mark Brezer will focus on his duties as president and director during a period of company growth and expansion into international markets. 

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) is a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America. The company’s flagship properties are located in the Red Lake Mining District of Ontario, Canada, renowned for over 30 million ounces of historic gold production. Other key projects extend into the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. The company’s management team is led by dedicated professionals, aiming to maximize shareholder value while employing modern exploration techniques and principles to achieve its goals.

The mission of StraightUp Resources is to maximize shareholder wealth through mineral discoveries at projects with robust potential, maintain long-lasting partnerships, and continue to focus on the acquisition, development and exploration of mineral resource properties in North America. The company’s objective is to continue to locate and develop economic, precious and base metal properties of merit.

The company’s 10,000-hectare (almost 25,000 acres) RLX Projects are contiguous to various Evolution Mining, Great Bear Resources, Pacton Gold and Dixie Gold properties. Its 2,000-hectare (just under 5,000 acres) Belanger Project is contiguous to Infinite Ore’s Fredart and Garnet/Arrow properties. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and Ferdinand Gold properties located in the Red Lake District, a location touted as having one of the best metal-endowed greenstone belts in the world. The Bear Head Gold Project is located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp and 14 km northeast of the former gold mine, Golden Patricia. It amassed 620,000 ounces of gold at an average of 15.2 g/t Au from 1988-1997. The property is bordered by an Australian miner massive gold project. Known gold occurrences are already mapped on the Bear Head property, as are previous drill holes and results. Once the data is re-examined, an exploration budget and subsequent plans will be announced by the company.


Ontario’s Red Lake Mining District is one of Canada’s most prolific gold mining districts, renowned for its high-grade gold deposits. This is a mining-friendly, politically stable jurisdiction with a skilled labor force and infrastructure specifically built around meeting the needs of the mining industry.

RLX North & South Projects
At over 10,000 hectares, the RLX North and RLX South Projects represent a district-scale exploration opportunity. The RLX North and RLX South Projects are well positioned on-strike to the southeast of the district’s largest gold deposit (Red Lake Gold Mines – Evolution Mining). The project is adjacent to Great Bear Resources’ Sobel Project. Great Bear Resources is also in the process of evaluating the area for significant regional-scale structural controls and has proposed additional work on its neighboring project in the near term. These properties are highly accessible, with the southern boundary only eight kilometers from the paved highway into Red Lake, and can be accessed by forest service roads which traverse throughout the properties.

Belanger Project
Historic exploration work on the 2,000-hectare property has identified three significant surface exposures of gold, copper and silver. Early exploration work will focus on validating historic sampling results and following the occurrences along strike with a view to better understanding the nature and controls on mineralization. The property has excellent forest road access from the town of Ear Falls.

Ferdinand Gold Project
The Ferdinand property is situated within the southeastern extension of the Confederation-Uchi greenstone belt, one of the most metal-endowed greenstone belts in the world by square kilometer. It consists of 17 contiguous mining claims covering approximately 7,143 hectares (17,650 acres), located 13 kilometers northwest of the town of Slate Falls. Access is currently by logging roads, with forestry logging operations scheduled for expansion on the property. StraightUp recently completed a heliborne magnetic survey consisting of 1,994 line-km at 50m line spacings covering the entire property. The MAG survey was designed to provide geological and structural details of a 25km long southeast extension of the Confederation-Uchi greenstone belt along the Fry-Bamaji Deformation Zone.

Bear Head Gold Project
The Bear Head Gold Project comprises 31 mining claims totaling 1,944 hectares (4,800 acres) in the Meen-Dempster Greenstone Belt of the Uchi Subprovince, host to the Golden Patricia former gold mine, which produced 620,000 ounces of gold from 1988 to 1997. The Dorothy Main gold deposit owned by Ardiden lies only one kilometer from the Bear Head Gold Project. The Dorothy Main gold deposit holds noncompliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. The company looks forward to adding the Bear Head Gold Project to its exploration efforts, with a work program to be conducted later in the fall of 2021.

Management Team

Mark Brezer is CEO, President, and Director of StraightUp Resources Inc. He is a successful businessman and holds a Geography/Geology degree from the University of Arizona. He has worked as a Project Manager and has overseen quality control, environmental monitoring and safety programs related to road construction. He has also held roles in media relations and marketing. He has been actively involved in the research and investment of junior mining companies for over 25 years. Time in the field and personal interest led him into extensive first aid training, and he is certified as a paramedic and firefighter.

Daniel Cruz is CFO and Director at StraightUp Resources. He is an experienced financial industry professional, having worked for 12 years as a senior investment advisor at Canadian broker-dealers, where he gained experience in equity research, asset management, investor relations, corporate finance and venture capital. He was one of the youngest Senior Investment Advisors at Canaccord Financial Inc. in 2010. He is also the co-founder and current director of Liquid Media Group Inc., a Nasdaq-listed issuer. During his tenure as CFO, he helped that company list on Nasdaq and raise over $20 million.

Matthew Coltura is a Director at StraightUp Resources. He has a Bachelor of Business Administration from Okanagan College, where he specialized in finance. He has worked in the finance industry for more than three years. Currently, Mr. Coltura is the CFO of Cayenne Capital Corp. He was also a director of PreveCeutical Medical Inc. from July 2016 to September 2019, a director of Sproutly Canada Inc. (formerly Stoneridge Exploration Corp.) from March 2015 to July 2018, and, since March 2018, has worked as a financial specialist at Quip Finance.

StraightUp Resources Inc. (OTCQB: STUPF), closed Monday's trading session at $0.11301, even for the day. The average volume for the last 3 months is 2,000 and the stock's 52-week low/high is $0.10676/$0.26.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

Last year was a mixed bag of a year for Canadian marijuana investors. Speculation about the future of the sector fluctuated wildly as talks about federal legalization heated up in the United States and recreational cannabis prices reached historic lows. Additionally, players in the Canadian cannabis space are waiting with bated breath for the three-year review of the country’s cannabis legislation by federal lawmakers. The review began in December 2021, and the health minister will present the department’s findings and recommendations in 2023. If the long-overdue changes are made to the regulations governing edibles and cannabis drinks, we could see an explosion in the demand for the products of Canada-based companies, including BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Monday's trading session at $0.15, even for the day, on 107,425 volume with 30 trades. The average volume for the last 3 months is 107,425 and the stock's 52-week low/high is $0.1343/$1.20.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

Nemaura Medical (NASDAQ: NMRD)a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has appointed Dr. Arash (Ash) Ghadar as chief operating officer. Currently a non-executive director at Medilink Midlands, Ghadar served for 10 years as the technical director of London-based Datalink Electronics (Datalink), where he managed the design team as an autonomous entity within Datalink. In that capacity, he oversaw the day-to-day operations, business planning, legal affairs, finance, sales and business development of the design team. He also managed numerous technical projects for the company’s healthcare and industrial customers; those projects included product-development lifecycle, feasibility studies, design, development, prototyping, validation, certification, quality management and volume manufacturing. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations,” said Nemaura Medical CEO Dr. Faz Chowdhury in the press release. “He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting, that will be a true asset for the Company during the commercialization phase of our growth.” To view the full press release, visit

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.


Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Monday's trading session at $4.56, off by 2.1459%, on 10,034 volume with 67 trades. The average volume for the last 3 months is 10,034 and the stock's 52-week low/high is $3.95/$17.40.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study
  • The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study
  • HYPER-H21-4 should "de-risk" outcomes prior to Lexaria's planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease
  • Previous studies – HYPER-H21-1 and HYPER-H21-2 – have evidenced a remarkable, rapid, and safe drop in blood pressure with DehydraTECH-CBD

A little less than two months after Lexaria Bioscience (NASDAQ: LEXX) announced it was readying the study protocols for HYPER-H21-4, its most ambitious and comprehensive study yet, for submission to the Independent Review Board (“IRB”) with approval anticipated by January 2022 (, the company is celebrating the receipt of the approval ahead of schedule. 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $4.3, off by 1.3761%, on 29,852 volume with 178 trades. The average volume for the last 3 months is 29,852 and the stock's 52-week low/high is $3.779/$12.50.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has released its full-year and Q1 2022 revenue guidance. The company noted that it is looking for a full-year 2022 guidance of $46‑48 million, which is an increase of approximately 50% over 2021’s unaudited revenue, which was approximately $31.5 million. In addition, the company noted that its Q1 2022 is $11.5 million, which represents an 111% increase over last year’s guidance for the same period. According to the announcement, the Sequire platform last year saw an increase in both subscribers and functionality, which led to growth last year and contributes to the anticipated increase in this year’s guidance. “Our team did excellent work in 2021, meeting and exceeding our guidance,” said SRAX founder and CEO Christopher Miglino in the press release. “The nature of our annual contracts provides us exceptional visibility into revenue. We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M.” To view the full press release, visit

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Monday's trading session at $4.28, off by 0.925926%, on 187,526 volume with 1,307 trades. The average volume for the last 3 months is 187,526 and the stock's 52-week low/high is $2.91/$7.29.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • CEO to participate in panel discussion, fireside chat focusing on psychedelics
  • The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape
  • CYBN is implementing a three-pillar strategy

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $1.02, off by 4.6729%, on 967,895 volume with 1,962 trades. The average volume for the last 3 months is 967,335 and the stock's 52-week low/high is $0.95/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Scientists from the School of Medicine at Washington University have created a deep-learning model that can classify brain tumors using an MRI scan. One of the researchers involved in the study, Satrajit Chakrabarty, stated that the research was the first to identify the absence or presence of a tumor from an MRI scan and directly determine the tumor class. The most common types of intracranial tumors include acoustic neuroma, pituitary adenoma, meningioma, brain metastases, low-grade glioma and high-grade glioma. Each tumor type was documented via histopathology, which involves the surgical removal of tissue from the site of a cancer and assessing it under a microscope. Such studies demonstrating how to make it easier to obtain a positive diagnosis of brain tumors in a minimally invasive way provide a perfect complement to the work of companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that seek to develop novel formulations targeting brain cancers in the continuum of care for cancer patients.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.7196, off by 3.3835%, on 634,818 volume with 1,685 trades. The average volume for the last 3 months is 636,228 and the stock's 52-week low/high is $0.6701/$4.46.

Recent News


The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

  • Bitcoin saw many different milestones during 2021, including surpassing $1 trillion in market value
  • LQwD launched its PaaS,, on November 17, amidst the Adopting Bitcoin – A Lightning Summit in El Salvador
  • The Lightning Network has seen explosive growth since January 2021
  • LQwD’s corporate and operational update highlights several of the company’s achievements regarding funding, agreements to drive Bitcoin adoption and own Bitcoin deployment to procure additional Lightning Network nodes and provide liquidity for the platform

Bitcoin was officially launched 13 years ago on January 3, 2009, by Satoshi Nakamoto, the pseudonym used by the person or persons who created the cryptocurrency, wrote and published a dedicated white paper on the topic and deployed its initial implementation. As the world’s oldest cryptocurrency is celebrating its 13th anniversary, it does so after a period of significant achievement, with multiple major milestones and firsts attained in 2021 ( These milestones include:

  • Surpassing $1 trillion in market value – On February 19, 2021, bitcoin hit a $1 trillion market value for the first time
  • Becoming the legal tender of El Salvador – The state’s authorities passed a new law to that effect in June 2021
  • Launch of the first U.S. futures-based bitcoin ETF – In October, the ProShares futures-based bitcoin ETF made its market debut on the NYSE under the ticker “BITO”
  • Bitcoin pricing hitting an all-time high – In November, the price of bitcoin achieved a new record, reaching over $69,044, according to CoinGecko
  • 90% of the total bitcoin supply having been mined – As of December 2021, 90% of the total bitcoin supply has been mined, but the remainder of the coin is not expected to be mined until February 2140
  • First bitcoin upgrade in four years – The first upgrade to bitcoin since 2017 happened in November 2021 and was named Taproot

Leveraging the growing popularity of cryptocurrency is LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company focused on creating enterprise-grade infrastructure to drive bitcoin adoption by enabling easier user access to the Lightning Network. The company released a dedicated platform as a service (“PaaS”) for the Lightning Network,, in November. 

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.


The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Monday's trading session at $0.275, off by 5.0742%, on 34,400 volume with 7 trades. The average volume for the last 3 months is 34,400 and the stock's 52-week low/high is $0.25/$4.00.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Last year was a strong year for base metals such as copper, aluminum, zinc, nickel and steel despite the raging pandemic that affected numerous industries. For instance, the pandemic led to a reduction in the number of workers at mines, with most developing countries closing refineries and mines due to high rates of infection, which in turn impacted levels of production. Companies such as Glencore, BHP and Southern Copper even announced decreases in their levels of production as a result of the pandemic. The physical market’s tightness and the high copper price environment also prompted China to release a considerable amount of its strategic copper reserves to the market. China is the metal’s largest consumer globally as well as the biggest producer of refined copper. Even after this, however, the deficit in the international refined copper market grew deeper last year, hitting 900,000 tons, which is even higher than the metal’s 2020 deficit of 530,000 tons. Data from Bank of America backs this claim, with estimates showing that by 2025, a metric ton of copper could be going for $20,000. Bank of America also expects that the copper market will rebalance in 2023 and 2024 after incurring deficits in 2021 and 2022, before inventories begin declining again in 2025. With such a bullish forecast, players in the base metals segment such as Asia Broadband Inc. (OTC: AABB) are likely to see increased interest in their stocks.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Monday's trading session at $0.1552, off by 3.3624%, on 14,414,314 volume with 1,254 trades. The average volume for the last 3 months is 14.399M and the stock's 52-week low/high is $0.01175/$0.659.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment
  • Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA
  • Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland
  • Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research

In mid-December, Representative Earl Blumenauer circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted ( Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced details regarding its participation at today's HC Wainwright Bioconnect Virtual Conference. The company’s co-founder and CEO Matt Stang will present on Delic’s expansion strategy and industry outlook heading into 2022 and offer one-on-one meetings with investors. Interested parties should visit to register for the event, access Delic's presentation and sign up for a one-on-one meeting. To view the full press release, visit

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.1069, off by 1.0185%, on 66,120 volume with 18 trades. The average volume for the last 3 months is 66,120 and the stock's 52-week low/high is $0.0983/$1.038.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading